Insurance Analytics Market Size, Share & Trends Analysis Report By Component, By Application, By Deployment, By Enterprise Size, By End Use, By Region And Segment Forecasts, 2025 - 2030

Insurance Analytics Market Size, Share & Trends Analysis Report By Component, By Application, By Deployment, By Enterprise Size, By End Use, By Region And Segment Forecasts, 2025 - 2030

Endoscope Sterilization Market Trends

The global endoscope sterilization market size was estimated at USD 1.20 billion in 2024 and is projected to grow at a CAGR of 9.64% from 2025 to 2030. This growth can be attributed to the increasing volume of surgical procedures conducted annually, which contributes to a rise in healthcare-associated infections (HAIs) associated with endoscopes. The data published by the ASP International GmbH indicates that between January 2017 and February 2021, the FDA obtained 450 medical device reports related to patient infections or contaminations associated with urological endoscopes in the U.S., including three deaths caused by subsequent bacterial infections. As a result, Karl Storz temporarily recalled over 24 models of urological endoscopes, recommending sterilization procedures outlined only in the Instructions for Use due to concerns that chemical disinfection was insufficient for adequate decontamination. Such incidents of inadequate disinfection are expected to drive demand for low-temperature sterilization for endoscopes in the coming years.

The convergence of endoscopy and robotics has revolutionized surgical possibilities, providing improved visualization, unparalleled precision, and better patient outcomes. For instance, the endoscopic surgical system from Virtuoso has two needle-sized manipulators that are robotically controlled and operate from the tip of an endoscope to bring the stability and precision of robot-assisted surgery to rigid endoscopy. Moreover, increasing numbers of successful clinical trials are expected to boost product approvals. In January 2023, Agilis Robotics, a prominent developer of flexible robotic instruments, successfully completed the second round of live animal testing with its proprietary robot for endoscopic surgery. The test results were satisfactory and demonstrated promising outcomes for the efficacy, accuracy, and safety of the firm's medical robotic system. Thus, increasing the integration of robotics in endoscopic surgery will lead to a rise in the number of procedures, thereby driving market growth.

Growing investments and funding for developing sterilization devices for endoscopes are expected to drive segment growth in the coming years. For instance, in 2020, Brighton Development secured approximately USD 0.99 million for Phase 2 of their project aimed at generating the necessary backup data to meet FDA requirements for commercializing the inside-out sterilization method. Once approved by the FDA, this technique can offer a cost-effective low-temperature sterilization solution suitable for plastic endoscopic devices that cannot be autoclaved due to the risk of melting plastic components. As a result, increasing investments in such initiatives are likely to bolster market growth throughout the forecast period.

In addition, the increasing prevalence of chronic diseases and the aging population further contribute to market growth. For instance, according to the data published by Statistics Sweden in May 2022, 8% of the Swedish population is anticipated to be 80 years or older by 2040, compared to 5% in 2022. Moreover, the WHO estimates that the number of individuals aged 80 years or older worldwide will triple within 30 years, i.e., from 2020 to 2050, to reach 426 million.

The increasing launch of novel products by industry participants is anticipated to propel the market growth. For instance, in May 2023, Ahlstrom launched the next-generation simultaneous sterilization wrap, Reliance Fusion, which would enhance the efficiency of sterilizing surgical equipment trays at hospitals. Such novel product launches by industry players are expected to drive market growth in the coming years.

Global Endoscope Sterilization Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global endoscope sterilization market report based on the product, type, device type, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Sterilizers

o Ethylene oxide sterilizers

o Hydrogen peroxide sterilizers

o Others

• Liquid Chemical Sterilization Systems
• Automated Endoscope Reprocessors (AERs)
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Flexible Endoscopes

o Single-channel Flexible Endoscopes

o Dual-channel Flexible Endoscopes

o Triple-channel Flexible Endoscopes

• Rigid Endoscopes

o Single-channel Rigid Endoscopes

o Dual-channel Rigid Endoscopes

• Device Type Outlook (Revenue, USD Million, 2018 - 2030)
• Colonoscopes
• Bronchoscopes
• Duodenoscopes
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Norway

o Denmark

o Sweden

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait"
"Recombinant cell Culture Supplements Market Growth & Trends

The global recombinant cell culture supplements market size is estimated to reach USD 2.44 billion by 2033 and is anticipated to grow at a CAGR of 12.83% from 2025 to 2033, according to a new report by Grand View Research, Inc. The advancements in recombinant technology and growing demand for biopharmaceuticals are some of the factors anticipated to drive market growth.

The increasing global demand for biologics, vaccines, and cell-based therapies has accelerated the need for advanced cell culture supplements. These supplements are essential for promoting optimal cell growth, enhancing protein production, and ensuring the long-term viability of cells during biomanufacturing. As biopharmaceutical companies scale up production to meet growing healthcare needs, cell culture supplements are expected to ensure the efficiency and consistency of these therapeutic products. Thereby propelling the demand for recombinant cell culture supplements over the forecast period.

The COVID-19 pandemic significantly accelerated the demand for recombinant cell culture supplements as global efforts to develop vaccines and therapeutics intensified. These supplements, are supported in scaling up vaccine production, ensuring consistent cell growth, and enhancing protein expression. The urgent need for efficient, high-quality manufacturing processes during the pandemic highlighted the importance of recombinant supplements, driving innovation and investment in biomanufacturing technologies and boosting market growth.

However, the high production cost of recombinant cell culture supplements is expected to limit the market's growth. The production of recombinant cell culture supplements involves advanced technology, specialized facilities, and skilled personnel, all of which contribute to high operational costs. These expenses can be a barrier for smaller companies or research labs with limited budgets, making it difficult for them to adopt these supplements.

Recombinant Cell Culture Supplements Market Report Highlights

• Based on product, the recombinant albumin segment held the largest revenue share of 30.99% in 2024 and is anticipated to grow at the highest CAGR over the forecast period. Moreover, Recombinant cytokines are anticipated to grow at a significant CAGR over the forecast period. This is attributed to the increasing demand for personalized medicine, advancements in immunotherapy, and the rising focus on chronic disease treatments.
• Based on type, the powder segment dominated the market with the largest revenue share in 2024. Powdered recombinant cell culture supplements are preferred due to their ease of storage, longer shelf life, and cost-effectiveness. However, liquid is anticipated to grow at the fastest CAGR over the forecast period.
• Based on the application, the biopharmaceutical production segment held revenue share of 60.22% in 2024. This growth is driven by the increasing demand for biologics, vaccines, and cell-based therapies, which require advanced cell culture systems and recombinant supplements for large-scale production. However, regenerative medicines are anticipated to grow at the fastest CAGR over the forecast period.
• Based on end use, the pharmaceutical & biotechnology companies segment dominated with the largest share of 38.83% in 2024. However, CDMOs are expected to grow at the fastest CAGR over the forecast period.
• Based on region, the North America region dominated the market with a share of 37.43% owing to factors such as strong research and development in biotechnology, medicine, and therapeutics, coupled with significant government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Please note The report will be delivered in 2-3 business days upon order notification.